Table 3:

Primary hemostasis, coagulation and inflammatory parameters* according to ABO blood type, factor V Leiden R506Q and prothrombin G20210A in the Copenhagen General Population Study

CharacteristicABO blood type, mean ± SEFactor V Leiden R506Q, mean ± SEProthrombin G20210A, mean ± SE
O n = 22 403 (39%)Non-O n = 34 557 (61%)p valueNoncarrier n = 52 103 (91%)Heterozygous n = 4 730 (8%)Homozygous n = 127 (0.2%)p valueNoncarrier n = 55 770 (98%)Heterozygous n = 1 183 (2%)Homozygous n = 6 (0.01%)§p value
Primary hemostasis
 Platelets, 109/L280 ± 0.5281 ± 0.40.1281 ± 0.3280 ± 1.0281 ± 6.30.6281 ± 0.3285 ± 2.1275 ± 270.1
 Mean platelet volume, fL7.7 ± 0.0067.7 ± 0.0050.37.7 ± 0.0047.7 ± 0.017.6 ± 0.070.57.7 ± 0.0047.7 ± 0.038.1 ± 0.50.3
Coagulation
 INR, ratio0.993 ± 0.002 0.994 ± 0.001< 0.0010.992 ± 0.0011.010 ± 0.0041.119 ± 0.0430.10.994 ± 0.0010.991 ± 0.0091.008 ± 0.039< 0.001
 Coagulation factor103.38 ± 0.16 103.68 ± 0.130.02103.63 ± 0.1103.04 ± 0.494.88 ± 3.10.4103.50 ± 0.1106.76 ± 0.897.00 ± 14< 0.001
 II + VII + X, %
 APTT, s29.4 ± 0.0328.4 ± 0.02< 0.00128.8 ± 0.0228.8 ± 0.0629.0 ± 0.320.628.8 ± 0.0229.9 ± 0.130.5 ± 1.3< 0.001
 Fibrinogen, μmol/L11 ± 0.0211 ± 0.020.111 ± 0.0111 ± 0.0411 ± 0.350.211 ± 0.0111 ± 0.0810 ± 0.620.02
Inflammation
 CRP, mg/L2.7 ± 0.032.8 ± 0.030.052.7 ± 0.022.6 ± 0.063.3 ± 0.830.52.7 ± 0.022.9 ± 0.152.5 ± 1.240.01
 Leukocytes, 109/L7.42 ± 0.027.38 ± 0.010.017.39 ± 0.017.43 ± 0.037.44 ± 0.160.037.39 ± 0.017.43 ± 0.066.38 ± 0.500.6
 Complement C3, g/L1.14 ± 0.0011.15 ± 0.001< 0.0011.14 ± 0.0011.14 ± 0.0031.16 ± 0.0211.01.14 ± 0.0011.15 ± 0.0061.08 ± 0.0800.1
  • Note: APTT = activated partial thromboplastin time, CRP = C-reactive protein, INR = international normalized ratio, SE = standard error.

  • * Unadjusted values from study entry are presented because we were examining differences by genotypes usually unconfounded by cardiovascular risk factors.

  • Numbers vary slightly depending on availability of measurements.

  • Wilcoxen rank sum tests and tests for trend.

  • § One homozygous participant receiving warfarin was excluded.